Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Breast cancer (Tokyo, Japan)

Volumn 14, Issue 1, 2007, Pages 81-87

  Imai, Hirohisa ^a   Kuroi, Katsumasa ^a   Ohsumi, Shozo ^a   Ono, Michikazu ^a   Shimozuma, Kojiro ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; LETROZOLE; NITRILE; TAMOXIFEN; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; QUALITY ADJUSTED LIFE YEAR; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; QUALITY-ADJUSTED LIFE YEARS; TAMOXIFEN; TRIAZOLES;

EID: 34247551377     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.2325/jbcs.14.81     Document Type: Review

References (16)